19 results about "Astragaloside IV" patented technology

The invention belongs to the technical field of biomedical materials, and particularly relates to astragaloside-loaded conductive hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: uniformly mixing a methylacrylic anhydride gelatin aqueous solution with an organic solvent solution of astragaloside, and carrying out ultraviolet light cross-linking curing to form methylacrylic anhydride gelatin / astragaloside hydrogel; soaking the obtained hydrogel in hydrochloric acid containing a free radical initiator; then soaking and polymerizing in an aniline ethanol solution; and soaking and purifying to obtain the methylacrylic anhydride gelatin-polyaniline conductive hydrogel loaded with astragaloside. In-vitro experiments prove that the compound has a certain anti-inflammatory effect, can induce neural stem cells to be directionally differentiated into neurons and oligodendrocytes, and is beneficial to promoting nerve regeneration and myelin sheath formation; finally, in-vivo experiments prove that the composition can improve the athletic ability and tissue function recovery of SCI rats, and has a good application prospect.

The invention provides lactobacillus reuteri GY-18 and application thereof in increasing the content of astragaloside, and belongs to the technical field of microorganisms, fermentation and natural product biotransformation. The lactobacillus reuteri GY-18 capable of improving the content of astragaloside in a fermented astragalus membranaceus product is obtained through screening, the lactobacillus reuteri GY-18 is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC M 20252796, and the lactobacillus reuteri GY-18 can be used for improving the content of astragaloside in the fermented astragalus membranaceus product. The lactobacillus reuteri GY-18 can secrete acetylxylan esterase for promoting conversion of astragaloside into astragaloside IV, has efficient specificity on conversion of astragaloside into astragaloside IV, and is high in conversion capacity; according to the method, the content of astragaloside IV is remarkably increased within 24 hours in a semi-solid state fermentation mode, and the method has good practicability.

The invention relates to the technical field of medicines for treating intestinal ischemia-reperfusion injury, and discloses a medicine for treating intestinal ischemia-reperfusion injury and a preparation method thereof. Comprising 10 to 25 parts of rosmarinic acid, 5 to 15 parts of betaine, 3 to 10 parts of glutamine, 10 to 25 parts of salvianolic acid B, 5 to 15 parts of astragaloside, 3 to 10 parts of ginsenoside Rg1, 2 to 8 parts of curcumin, 5 to 12 parts of ophiopogon japonicus polysaccharide, 2 to 6 parts of notoginsenoside R1, 3 to 7 parts of total flavonoids of oldenlandia diffusa and 4 to 9 parts of angelica sinensis polysaccharide. The medicine disclosed by the invention can be used for relieving intestinal edema, repairing oxidative injury, clearing excessive ROS, improving SOD activity, blocking oxidative stress injury, inhibiting epithelial cell apoptosis, reducing intestinal permeability and maintaining mucous membrane integrity, and has an excellent treatment effect on intestinal ischemia reperfusion injury.

This invention discloses a thin-layer chromatography method for identifying health tonics, comprising: preparing a test sample solution; preparing a reference herbal solution; preparing a reference standard solution; taking 1-2 μl of each of the above three solutions and spotting them separately in strip form on the same high-efficiency silica gel G thin-layer plate; using the upper layer solution of n-butanol-ethyl acetate-water in a volume ratio of 1-8:0.1-1:1-7 as the developing solvent; developing to approximately 15 cm; removing, air-drying, spraying with 10% sulfuric acid ethanol solution, and heating at 105°C until the spots are clearly visible; and examining under sunlight and ultraviolet light (365 nm). This invention can effectively solve the problem of astragaloside A and ginsenoside R in health tonics through a simple processing method. f The problem of mutual interference. This provides a basis for the identification of health wines and a reference for product quality control.

The invention belongs to the technical field of medicines for treating polycystic ovarian syndrome, and particularly relates to application of astragaloside IV and a compound thereof in preparation of a medicine for treating polycystic ovarian syndrome and the medicine. The compound is prepared from the following raw materials: mannitol, vitamin B3 and vitamin B9, wherein the mass ratio of the mannitol to the vitamin B3 to the vitamin B9 is (0.5-1): (0.5-1): 1; the mass ratio of the astragaloside IV to the compound is 1: (2-4). The mannitol, the vitamin B3 and the vitamin B9 are used for activating a PPAR gamma channel, increasing the relative expression quantity of PPAR gamma and inhibiting proliferation of human ovarian granular cells. And the mannitol, the vitamin B3, the vitamin B9 and the astragaloside IV are mixed for use, so that the effect is optimal.

The invention discloses an application of a compound composition containing astragaloside IV in preparation of a medicine for resisting plateau fatigue, and the compound composition containing astragaloside IV is prepared from the following raw materials in parts by weight: 500 to 2000 parts of astragaloside IV, 5000 to 20000 parts of ginsenoside Rg1, 2 to 5 parts of vitamin D3 and 30000 to 150000 parts of puerarin. Animal experiments prove that the compound composition can relieve plateau exercise fatigue, improve the hypoxia tolerance, exercise fatigue resistance and oxidative stress resistance of a body and improve the comprehensive exercise performance of the body. According to the invention, the defect of single-component efficacy is overcome, a compound preparation is designed in a targeted manner, an innovative and feasible compound combination is provided, and a new scheme is provided for promoting athletic performance under plateau hypoxia.

The invention discloses a multi-index quality control method of Naoxinan capsules, and relates to the technical field of medical drugs, the method adopts a high performance liquid chromatography to establish a wavelength characteristic spectrum for detection, and the method specifically comprises the following steps: detecting a characteristic spectrum 1 under the wavelength of 260nm: taking a puerarin reference substance peak (marked as 1 (S)) as a reference, and detecting the characteristic spectrum 2 under the wavelength of 260nm; five characteristic peaks are required to be presented in the chromatogram of the test sample, and the similarity between the retention time of the five characteristic peaks and the contrast characteristic chromatogram is greater than or equal to 0.90; and / or detecting a characteristic spectrum 2 under the wavelength of 320nm: by taking a puerarin reference substance peak (marked as 1 (S)) as a reference, requiring that five characteristic peaks appear in a chromatogram of the test sample, and the similarity between the retention time of the five characteristic peaks and the contrast characteristic spectrum is greater than or equal to 0.90. According to the invention, five active ingredients such as flavonoids (puerarin), saponins (astragaloside) and phenolic acids (tanshinol) are covered through a wavelength characteristic spectrum (260nm and / or 320nm).

The application discloses a culture medium for improving in-vitro aging of oocytes after ovulation and application thereof. The culture medium is prepared by adding 0.1-30 muM of astragaloside IV into an oocyte culture solution. The culture medium is safe, non-toxic and free of side effects, can reduce the oocyte fragmentation rate, active oxygen level and abnormal spindle rate of the oocytes after 24 hours of in-vitro culture, can significantly improve the mitochondrial membrane potential, in-vitro sperm binding capacity, in-vitro fertilization pronucleus rate and cleavage rate of the mature oocytes after 24 hours of in-vitro culture, and can improve the quality of the late embryos. The application of the culture medium provides favorable support for assisted reproductive technology, and has a good application prospect.

The invention relates to a pharmaceutical composition with an effect of improving blood-brain barrier injury after cerebral infarction thrombolysis. The pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 1-100 parts of astragaloside, 0.25-25 parts of tanshinol and 1-100 parts of notoginsenoside R1.

The present application relates to a new medical use of Astragaloside IV, and particularly relates to the use of Astragaloside IV in the preparation of a medicine for promoting the osteogenic differentiation of BMSCs of a patient with congenital scoliosis. The present application discloses that Astragaloside IV can specifically up-regulate the expression of WISP2, and then activate the Wnt / β-catenin pathway, significantly improve the alkaline phosphatase activity, mineralization capacity and osteogenic related gene expression of CS-BMSCs. Through cell induction, animal implantation and targeted sustained-release preparation and other experimental means, the present application confirms the safety and effectiveness of Astragaloside IV in repairing CS-related osteoporosis, and has a good application prospect.

The application belongs to the technical field of biological medicine, and provides application of astragaloside IV in preparation of a medicine for treating advanced ovarian cancer. The application analyzes and studies a targeting effect of AS-IV on CD276, determines a molecular mode of covalent combination of AS-IV and CD276, identifies a molecular mechanism of combination of AS-IV and CD276 through an E3 ubiquitin ligase and activation of an mTORC1 pathway of NK cells, and determines application potential of AS-IV in enhancement of NK cell anti-tumor immunity in preparation of an OC immunotherapy medicine.

The invention discloses a process for preparing astragaloside through multi-step enzymolysis. According to the invention, windowing control is carried out around the astragaloside wall opening, releasing, transferring and grading process through a multi-step enzymolysis, segmented ultrasonic permeation / strengthening and ultrafiltration and nanofiltration series preparation process. The astragaloside yield and the crude product purity are obviously improved.

The invention belongs to the technical field of traditional Chinese medicine processing, and particularly relates to an astragaloside extraction method. The active ingredient astragaloside IV of astragalus membranaceus is directly extracted by using a natural deep-eutectic solvent extraction method, betaine and lactic acid are mixed and dissolved according to the mass ratio of 5: (25-35) to obtain a lactic acid-betaine deep-eutectic solvent, astragalus membranaceus powder is added, extraction is performed through specific process parameters, the content of astragaloside IV in the extracted product is up to 4.2 mg / g, and the content of astragaloside IV in the extracted product is up to 4.2 mg / g. Compared with a traditional ethanol extraction method, the extraction rate is increased by 25%. The method has the advantages of simple and rapid process flow and easiness in industrial production.

This invention relates to a method for constructing and applying an HPLC fingerprint of a traditional Chinese medicine granule for invigorating qi and promoting blood circulation, belonging to the field of biomedical technology. This invention provides a method for establishing an HPLC fingerprint of the traditional Chinese medicine granule Qishen Jianxin Granules and its application. The application includes using HPLC fingerprinting with isoflavone glucoside, glycyrrhizin, and ammonium glycyrrhizate as references to achieve quality control of the Qishen Jianxin Granules, and quantifying key components by determining the content of astragaloside A. This invention provides a traditional Chinese medicine granule with definite efficacy, strict quality control, and stable controllability, and its quality control method. It achieves overall characteristic control through HPLC fingerprinting and quantifies key components through the determination of astragaloside A content, providing dual assurance of preparation quality and efficacy. It is highly practical and has good industrialization and promotion value.

The invention discloses a method for detecting astragaloside IV in kernel-bighead atractylodes rhizome stomach-invigorating granules. The method for detecting the astragaloside IV in the kernel-bighead atractylodes rhizome stomach-invigorating granules comprises the following steps: step 1, preparing a reference substance solution; step 2, preparing a test solution; and step 3, respectively and precisely sucking the reference substance solution and the test solution, injecting into a liquid chromatograph, and determining by an evaporative light-scattering detector. The detection method established by the invention is rapid and accurate in analysis, free from interference of negative samples, strong in specificity and good in reproducibility and stability, the peak pattern of the chromatographic peak of the obtained chromatogram is relatively good, and the quality of the kernel-bighead atractylodes rhizome stomach-invigorating granules can be objectively evaluated.

The present application relates to the field of targeted drugs, and discloses a drug self-assembly system for treating chronic heart failure, and a preparation method and application thereof, the drug self-assembly system comprising: a drug active component (including astragaloside and tanshinone II A), a phosphatidylated triphenylphosphine compound and a biomimetic membrane (a product obtained after mixing of macrophage membrane fragments and myocardial cell membrane fragments); the phosphatidylated triphenylphosphine compound is embedded on the surface of nanoparticles self-assembled by the drug active component, and the biomimetic membrane is wrapped on the outer layer of the modified nanoparticles; the encapsulation rate of the drug active component in the drug self-assembly system is 80-95 wt%. The drug self-assembly system provided by the present application improves the encapsulation rate of the drug active component and can realize efficient drug delivery, has good stability and high safety, has low preparation process cost, and has good batch production and clinical transformation prospects.

The invention discloses an anti-bladder cancer traditional Chinese medicine compound tablet based on function modularization and a preparation method. Comprising the following components: a body resistance strengthening module: an astragaloside-selenium nano-composite, an ophiopogonin-selenium nano-composite and rehmannia lipidosome; an evil eliminating module: spreading hedyotis herb PLGA nanoparticles and phellodendrine / coix seed oil microemulsion; and the collateral dredging module comprises centipede-salvia miltiorrhiza sustained release microspheres and achyranthes bidentata-lysimachia christinae According to the invention, a three-module design of strengthening body resistance, eliminating evil and dredging collaterals is created for the first time, and the action mechanism of each path is clear. When the drug is combined with a chemotherapeutic drug gemcitabine, the synergistic interaction index reaches 1.31, and the tumor volume reduction rate is increased to 89% from 62% of single drug treatment.

The invention belongs to the technical field of analytical chemistry, and particularly relates to a method for determining the content of astragaloside IV in astragalus fine granules. The method provided by the invention is a high performance liquid chromatography method, adopts an ultraviolet detector which is most commonly used in liquid chromatography, has higher sensitivity for detecting astragaloside with lower content in a preparation, optimizes a method for preparing a test sample, enables the preparation process to be simpler and more convenient to operate, shortens the preparation time, saves the detection cost, and has a better application prospect.

The invention belongs to the technical field of stem cell exosome biological preparation, and particularly relates to a human umbilical cord blood mesenchymal stem cell exosome (hUCMSCs-Exo) based on astragaloside (AS-IV) induction as well as a preparation method and application thereof. According to the human umbilical cord blood mesenchymal stem cell exosome induced based on astragaloside, astragaloside and jasmonic acid methyl ester serve as induction components, intervention induction is conducted in the stem cell culture process, the stem cell exosome can be induced to generate muscle attenuation resisting activity, and the human umbilical cord blood mesenchymal stem cell exosome can be applied to products for improving muscle attenuation and related symptoms of the muscle attenuation. The composition has the advantages of safety, long-term use, no side effect and the like.